Key Highlights
- FDA awarded priority review status to two supplemental Biologics License Applications for KEYTRUDA and KEYTRUDA QLEX combined with Padcev therapy.
- These applications focus on treating muscle-invasive bladder cancer patients eligible for cisplatin-containing chemotherapy regimens.
- Regulatory decision deadline scheduled for August 17, 2026.
- Phase 3 KEYNOTE-B15 clinical trial results demonstrating enhanced survival rates form the foundation of both applications.
- Approval would establish this combination as the inaugural perioperative therapy for MIBC patients across all cisplatin eligibility categories.
Merck has secured another promising opportunity to expand its flagship oncology treatment KEYTRUDA, with the FDA awarding priority review designation to two applications aimed at bladder cancer patients.
The pharmaceutical giant announced Monday that the FDA has accepted two supplemental Biologics License Applications covering KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph). Both submissions propose using these therapies alongside Padcev (enfortumab vedotin-ejfv) in treating muscle-invasive bladder cancer patients who qualify for cisplatin-containing chemotherapy protocols.
The regulatory agency established an August 17, 2026 target date under the Prescription Drug User Fee Act guidelines.
The FDA reserves priority review designation for treatments demonstrating potential for significant therapeutic advances in addressing serious medical conditions. This classification generally reduces the evaluation period to approximately six months, substantially faster than the conventional ten-month timeline.
Clinical Trial Results
Both applications draw their supporting evidence from the Phase 3 KEYNOTE-B15 clinical study. This trial demonstrated enhanced survival benefits among muscle-invasive bladder cancer patients receiving the KEYTRUDA and Padcev combination regimen.
While Merck refrained from disclosing detailed trial metrics in Monday’s statement, the FDA’s priority review decision indicates the agency recognizes the data’s potential to transform clinical practice standards.
Presently, the approved indication for KEYTRUDA combined with Padcev encompasses adult patients diagnosed with locally advanced or metastatic urothelial cancer across the United States, European Union, Japan, and additional international markets.
These pending applications seek to broaden that authorization into earlier disease stages — specifically the muscle-invasive phase — where therapeutic goals typically focus on achieving cure.
Pioneering Treatment Classification
Should regulatory approval be granted, the KEYTRUDA and KEYTRUDA QLEX combinations with Padcev would represent the first perioperative treatment options for MIBC patients across all cisplatin eligibility categories.
This distinction carries significant clinical importance. The current authorization covers MIBC patients unsuitable for cisplatin-based chemotherapy. These new applications would encompass cisplatin-eligible patients as well — substantially expanding the addressable patient population.
Perioperative treatment encompasses therapy administered before, during, or after surgical intervention, which represents the standard care approach for muscle-invasive bladder cancer. Securing priority review status for this treatment setting positions Merck favorably from a regulatory standpoint approaching the August decision milestone.
KEYTRUDA QLEX represents a subcutaneous formulation of pembrolizumab, enabling delivery through injection beneath the skin rather than traditional intravenous infusion. This administration method could provide practical advantages compared to standard IV delivery.
Merck’s shares advanced 3.13% Monday following the announcement. The August 17 target date now represents a critical milestone for investors monitoring the company’s oncology development portfolio.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
